• <nav id="kqke8"></nav>
  • <input id="kqke8"><u id="kqke8"></u></input>
    <nav id="kqke8"><tt id="kqke8"></tt></nav><nav id="kqke8"></nav>
  • <input id="kqke8"></input>
    <input id="kqke8"><strong id="kqke8"></strong></input>
  • <nav id="kqke8"></nav>

    Overview

    China Pharma IP Summit is a serial event dedicated to pharmaceutical IP protection, and so far we have hold 2 sessions in the year of 2016 and 2017. Government agencies, pharmaceutical/biotech companies, law firms/ IP agencies and other IP solution providers have been invited to attend and we discussed lots of hot issues. Meanwhile, the event has been a good networking platform for industry experts both from local China and abroad.

    2017 is a year of great significance in China pharmaceutical industry. On May 2017, China Food and Drug Administration (CFDA) issued Policy Notice No. 55, entitled “Policies Relevant to the Protection of the Rights and Interests of Innovators for the Encouragement of Innovation in Drugs and Medical Devices”. On October 2017, the Opinions on Deepening the Review and Approval System Reform and Encouraging the Drug and Medical Device Innovation was officially issued, clearly putting forward the establishing patent linkage system, launching pilot program on drug patent extension, completing data protection and implementing list of marketed drugs. At the moment, China is conducting legislation for patent linkage and patent extension, which draws lots of attention.

    In terms of intellectual property judicial, on Feb 2018, General Office of the CPC and General Office of the State Council issued Strengthening the Intellectual Property Judicial Reform and Innovation, which is the first guiding document regarding to intellectual property judicial. Pharmaceutical is heavily relied on IP protection, and we predict the guiding document will have influence on pharmaceutical IP litigation in China.

    Based on the background, we are glad to inform that 3rd China Pharma IP Summit 2018 will be hold on 24th -26th October in Beijing, providing a platform to discuss updated policies and hot issues.

    Through the event, you will have chance to:

    1. Follow the latest development of patent linkage and patent term extension reform in China

    2. Understand the differences and updated requirements of examination standards, patent invalidation, patent litigation in China, US, EU, Japan and other region.

    3. Learn IP management experience from pharmaceutical company

    4. Meet you clients/partners fact to face and interact with industry peers

    The participants are mainly from pharma/biotech companies, law firms, IP/patent agencies, IP/patent solution providers, governments, relevant associations, research institutes. If you would like to attend or sponsor our summit, please feel free to call / email us to reserve your seats ASAP!

    Thanks again for your attention and looking forward to your participation!



    Agenda:

    Day1:24, Oct. 2018


    Day1 Morning: Policies Updated in China


    0730 Registration


    0840


    Opening Remarks

    Qingkui Zhang, Director, Pharmaceutical IP Research Committee of Chinese Pharmaceutical Association



    0900


    Pharmaceutical IP Index and Evaluation of Pre-Revenue Pharmaceutical Innovators Going Public in Hong Kong

    Pharmaceutical companies developing new drugs in clinical trials can now file IPO in Hong Kong without any revenue if they have strong long term patent rights. Tony Chen (Jones Day) and Matthew Chervenak (General Biologic) will introduce a Pharmaceutical IP Index to measure true economic exclusivity of innovative drugs by taking into account patent term, patent strength, regulatory data protection and other factors. They will demonstrate how π Value will help the market assess the long term IP value of innovative pharmaceutical companies in China and explain the potential impact of pharmaceutical IP reform in China on innovation.

    Tony Chen, Partner, Jones Day

    Matthew Chervenak, Founder and CEO, General Biologic (GBI)



    0930

    Panel Discussion: Pharmaceutical Innovation and IP Protection in China

    China is exploring to establish patent linkage and patent term extension system. The industry is waiting for more detailed implementation rules. We will invite experts to share the updates and developments.

    Moderator:

    Yongshun Cheng, Director, Beijing Intellectual Property Institute

    Panelists:

    Qingkui Zhang, Director, Pharmaceutical IP Research Committee of Chinese Pharmaceutical Association

    Tony Chen, Partner, Jones Day

    Taoxi Lin, IP Director, HEC Group

    Elaine Li, Partner, ADVANCE CHINA IP LAW OFFICE



    1040
    Coffee Break


    1110

    Projecting Characteristics and Trends of Pharma Patent Invalidation in China under the New Patent Linkage System

    Juhua Luo, Deputy Director of Chemical Patent Department, CCPIT Patent and Trademark Law Office

    1150

    The Patent Linkage for Pharmaceuticals -A Worldwide Perspective

    Yehudah Livneh, Strategic IP Consultant;

    Former General Patent Counsel and VP Corporate IP and Legislative Affairs, Teva Pharmaceuticals



    1240 Lunch Buffet


    Day 1 Afternoon: Focus on US


    1400

    Chair Speech

    Ningling Wang,Shanghai Office Managing Partner, Finnegan, Henderson, Farabow,Garrett & Dunner, LLP



    1405

    Strategies to Improve Certainty and Reduce Costs in Paragraph IV Litigation

    Shashank Upadhye, Founding Partner, Amin Talati Upadhye, LLP



    1440


    Business Development of Pharma Companies in the Era of Big Data: Leveraging Patent Information in Strategic Partnership Scouting and Drug Development

    Li Miao, IP Consultant, LexisNexis



    1515

    Coffee Break



    1550

    Navigating the IP/FDA Exclusivity Waters Recent Developments Affecting The Journey to 505(b)(1), 505(b)(2), ANDA and Biologics Approval in the US

    Christopher Griffith, Founding Partner, Green, Griffith & Borg-Breen LLP



    1625

    Navigating the Safe Harbor Provision of the Hatch-Waxman Act

    Alyson Wooten, Counsel, Kilpatrick Townsend & Stockton LLP



    1700

    Panel Discussion:Strengths and Risks in the Use of Patents to Protect Market Exclusivity in the US

    Moderator:

    Ningling Wang,Shanghai Office Managing Partner, Finnegan, Henderson, Farabow,Garrett & Dunner, LLP

    Panelists:

    Janet Xiao, Partner, Morrison & Foerster LLP

    Cynthia Lan Martin, Senior Patent Attorney, AstraZeneca

    Steven H. Sklar, Member, Leydig, Voit & Mayer

    Yieyie Yang, Associate, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP



    1800 Cocktail  (Sponsored  by Womble Bond Dickinson (US) LLP


    Day2: 25, Oct. 2018


    Day2 Morning: Focus on China

    0830


    Chairman Opening Remark

    Chairman: Li Wu, Senior Consultant, AnJie Law Firm



    0840

    Pharmaceutical High Value Patent Cultivation

    Qiujuan Ma, Director for Pharmaceutical, Patent Examination Cooperation Center of SIPO



    0920

    Pharmaceutical Patent Trial in China

    Chi Su, Director of IP Case Guidance Research (Beijing) Base of the Supreme Peoples Court and President of Beijing IP Law Association; First President, Beijing Intellectual Property Court (Retired in Dec. 2017)



    1000

    Coffee Break

    1030

    Analyzing and Discussing Pharmaceutical Patent Infringement Litigation Case

    HENG DU LAW FIRM



    1110

    Panel Discussion: Regulatory Data Protection in China

    Moderator:

    Chen Yang, Senior Counsel, Sidley Austin LLP

    Panelists:

    Xu Yang, Patent Attorney, BeiGene, Ltd.

    Kent Yang, Head Patents China, Novartis Pharmaceuticals (China)

    Yue Yang, Director, International Center for Food and Drug Policy and Law,

    Shenyang Pharmaceutical University



    1145

    Panel Discussion: Hot Cases of Pharmaceutical Patent Invalidation in China and Implication

    Moderator:

    Li Wu, Senior Consultant, AnJie Law Firm

    Panelists:

    Xiaolan Ren, Director of Chemical Appeal Department, The Patent Reexamination Board of the CNIPA (National Intellectual Property Administration, PRC)

    Feng Xu, IP Director for China and Asia, AstraZeneca

    Nick Liu, Partner, AnJie Law Firm (Former Senior Judge at Intellectual Property Division of Beijing Higher Peoples Court)



    1235 Lunch


    Day2 Afternoon: Focus on EU


    1400

    Chair Speech

    Andreas Oser, Partner, Prüfer & Partner



    1405

    The Latest Developments at EPO (including pertinent case law)

    Klaus-Peter D?pfer, Director Biotechnology, Sector Healthcare-Biotechnology-Chemistry, EPO

    1440


    The Supplementary Protection Certificate in Europe and Potential Modification (including introduction of a manufacturing waiver)

    Andreas Oser, Partner, Prüfer & Partner

    1515

    Coffee Break

    1620


    Is your invention plausible? The rising importance of the “plausibility” hurdle in life science and pharmaceutical patents”

    Hsu Min Chung, Partner, HGF Limited



    1625

    Secondary Patents - Current Developments And Challenges in Europe

    Ute Kilger, Partner, Boehmert & Boehmert

    Markus Engelhard, Partner, Boehmert & Boehmert



    1700

    Panel Discussion: Patent Protection and Enforcement of First, Second or Further Medical Uses of Known Compounds/Pharmaceutical Products in Europe

    Moderator:

    Andreas Oser, Partner, Prüfer & Partner

    Panelists:

    Hsu Min Chung, Partner, HGF Limited

    Klaus-Peter D?pfer, Director Biotechnology, Sector Healthcare-Biotechnology-Chemistry, EPO

    Ute Kilger, Partner, Boehmert & Boehmert

    Markus Engelhard, Partner, Boehmert & Boehmert



    Day3: 26, Oct. 2018


    Day3 Morning: Other Region


    0830

    Chairman Opening Remark:

    Mahendra B. Thakre, General Manager – IPR Legal, Mylan Laboratories Limited



    0840

    Pharmaceutical Patent Protection and Patent Term Extension Regime in Japan

    Koichiro Morihira, Head of Intellectual Property, Astellas Pharma Inc.



    0920

    Optimizing Overseas Pharma M&A DecisionsBig Data Supported IP Due Diligence

    Chieh-Mei Wang, Vice President, ScienbiziP Consulting (Shen Zhen) Co., Ltd.



    1000

    Coffee Break



    1035

    The Generic Pharmaceutical in India and Patent Compulsory Licensing System

    Mahendra B. Thakre, General Manager – IPR Legal, Mylan Laboratories Limited



    1110

    US Updates and Effect on Pharmaceutical Companies

    Todd Volyn, Associate Patent Counsel, Johnson & Johnson



    1145

    Conference Closing Remark






     

      Media Partner

    天堂AV 国产 亚洲 日韩 制服